Ultragenyx Pharmaceuticals Announces Collaboration With Kyowa Hakko Kirin to Develop and Commercialize Phase 2-Stage KRN23 for X-Linked Hypophosphatemia
9/4/2013 12:46:21 AM
NOVATO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. today announced it has entered into a collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. (KHK), to develop and commercialize KRN23. KRN23 is a recombinant fully human monoclonal IgG1 antibody intended to treat X-linked hypophosphatemia (XLH). KHK is currently completing a Phase 1/2 study in adults with XLH in the US and Canada. The two companies plan to initiate a pediatric XLH program in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by